Combined use of autografting and non-myeloablative allografting for the treatment of hematologic malignancies and metastatic breast cancer.

A. Carella,G. Beltrami,E. Lerma,M. Cavaliere,M. Corsetti

DOI: https://doi.org/10.1007/978-1-4615-0919-6_5

Abstract:

What problem does this paper attempt to address?

[Clinical Observation of Gleevec Combined with Myeloablative Allogeneic Stem Cells Transplantation in Treatment of Chronic Myeloid Leukemia].

Yi Luo,Jie Pan,Ji-min Shi

DOI: https://doi.org/10.3785/j.issn.1008-9292.2007.04.006

2007-01-01

Abstract:OBJECTIVE:To observe the efficacy of Gleevec combined with myeloablative allogeneic stem cells transplantation(Allo-SCT) for the treatment of chronic myeloid leukemia (CML).METHODS:Nine patients with CML were treated with Gleevec before and after Allo-SCT, with 5 in the chronic phase (CP), 2 in the accelerated phase (AP) and 2 in the blast-crisis phase (BP). The donors were HLA matched identical siblings (n=7) and matched unrelated donors (n=2). The conditioning regimen is BuCy2. Mycophenolate mofetil combined with cyclosporin A and methotrexate was used for the prevention of acute GVHD.RESULTS:All patients achieved completed hemopoietic remission (HCR) treated with pre-transplant Gleevec. The median period to gain absolute neutrophil count>0.5x10(9)/L was 12 d (8 approximately 26 d) and that for platelet count>20x10(9)/L was 20 d (8 approximately 25 d). Three cases suffered from acute GVHD and 4 from chronic GVHD. All patients achieved completed engraftment and completed molecular remission. The rate of disease free survival was 88.9% after a median follow-up of 31 m (range 7 approximately 34 m).CONCLUSION:The treatment of CML consisting of myeloablative Allo-SCT combined with Gleevec before and after transplantation is an effective and safe method for CML.
Hla-Haploidentical Stem Cell Transplantation for Malignant Hematological Diseases Using G-Csf Mobilized Bone Marrow and Peripheral Blood Stem Cells

Yi Luo,Yamin Tan,Xiaoyu Lai,Jimin Shi,Weiyan Zheng,He Huang

DOI: https://doi.org/10.1182/blood.v116.21.2384.2384

IF: 20.3

2010-01-01

Blood

Abstract:Abstract 2384 Introduction: Allogeneic haematopoietic stem cell transplantation (HSCT) has been used to treat malignant hematological diseases. For patients who do not have a matched sibling donor or a matched unrelated donor (MUD) for transplantation, an eligible HLA-haploidentical donor can be identified rapidly in nearly all cases. However, HLA-haploidentical BMT has been associated with significant risks of complication, such as graft rejection and severe GVHD and infection. Materials and Methods: Thirty eight consecutive patients with malignant hematological diseases received HLA-haploidentical stem cell transplant from April 2008 to June 2010. Eligible patients were 9– 48 years of age with acute myeloid leukemia (n=10),acute lymphocytic leukemia (n=17), myelodysplastic syndrome(n=5), chronic myeloid leukemia (n=4), non Hodgkin lymphoma (n=2). Transplantation conditioning consisted of Ara-C (4 g/m2/d, i.v.) on day -10 and -9, Bu (9.6mg/kg i.v. in 12 doses) on day -8, -7 and -6, Cy (1.8 g/m2/d, i.v.) on day -5 and -4, Me-CCNU (250 mg/kg, i.v.) on day -3, and ATG (2.5 mg/kg/d i.v.) on day -5 to -2. The prophylaxis of aGVHD consisted of cyclosporine A (CsA), mycophenolate mofetil (MMF), and short-term methotrexate. Donors were primed with rhG-CSF (7.5 mg/kg per day) injected subcutaneous (s.c.). Bone marrow cells and peripheral blood stem cells(PBSC) were harvested in nineteen donors, and only PBSC were harvested in the other 19 donors. Results: Primary engraftment was achieved in all patients. All the patients achieved complete donor chimerism in the peripheral blood before day +28. Seven patients (18.4%) had grade I aGVHD, ten (26.3%) had grade II aGVHD, four(10.5%) had grade III aGVHD and four (10.5%) had grade IV aGVHD. II-IV aGVHD occurred in nine patients treated with bone marrow cells and PBSCs, the same number patients suffered from II-IV aGVHD treated with only PBSCs. Transplant related mortality within 100 days after transplantation was 15.8%. At a median follow-up of 10 months (range 2–28months), the overall survival was 68.4%. Conclusion: Haploidentical stem cell transplantation is relatively safe and efficient for the patients who have no HLA matched donors.The results require to confirm and show that G-BM combined with PBSC or G-PBSC from haploidentical family donors have equal effect. Disclosures: No relevant conflicts of interest to declare.
Steady-state low thermal resistance characterization apparatus: The bulk thermal tester.

B. Burg,Manuel Kolly,N. Blasakis,Dominic Gschwend,J. Zürcher,T. Brunschwiler

DOI: https://doi.org/10.1063/1.4936766

IF: 1.6

2015-12-09

Review of Scientific Instruments

Abstract:The reliability of microelectronic devices is largely dependent on electronic packaging, which includes heat removal. The appropriate packaging design therefore necessitates precise knowledge of the relevant material properties, including thermal resistance and thermal conductivity. Thin materials and high conductivity layers make their thermal characterization challenging. A steady state measurement technique is presented and evaluated with the purpose to characterize samples with a thermal resistance below 100 mm(2) K/W. It is based on the heat flow meter bar approach made up by two copper blocks and relies exclusively on temperature measurements from thermocouples. The importance of thermocouple calibration is emphasized in order to obtain accurate temperature readings. An in depth error analysis, based on Gaussian error propagation, is carried out. An error sensitivity analysis highlights the importance of the precise knowledge of the thermal interface materials required for the measurements. Reference measurements on Mo samples reveal a measurement uncertainty in the range of 5% and most accurate measurements are obtained at high heat fluxes. Measurement techniques for homogeneous bulk samples, layered materials, and protruding cavity samples are discussed. Ultimately, a comprehensive overview of a steady state thermal characterization technique is provided, evaluating the accuracy of sample measurements with thermal resistances well below state of the art setups. Accurate characterization of materials used in heat removal applications, such as electronic packaging, will enable more efficient designs and ultimately contribute to energy savings.
High activity of the new myeloablative regimen of gemcitabine/clofarabine/busulfan for allogeneic transplant for aggressive lymphomas

Jeremy Ramdial,Ruitao Lin,Peter F. Thall,Benigno C. Valdez,Chitra Hosing,Samer Srour,Uday Popat,Muzaffar Qazilbash,Amin Alousi,Melissa Barnett,Alison Gulbis,Terri Lynn Shigle,Elizabeth J. Shpall,Borje S. Andersson,Yago Nieto

DOI: https://doi.org/10.1038/s41409-024-02394-0

2024-09-29

Bone Marrow Transplantation

Abstract:Refractory aggressive lymphomas can be treated with allo-SCT, pursuing a graft-vs-lymphoma effect. While reduced intensity conditioning is safe, tumors often progress rapidly, indicating the need for more active conditioning regimens. The preclinical synergy we saw between gemcitabine (Gem), clofarabine (Clo) and busulfan (Bu) against lymphoma cell lines led us to study Gem/Clo/Bu clinically. Eligibility: age 12–65, refractory aggressive B-NHL, T-NHL or Hodgkin, with a matched donor. Infusional Gem was dose-escalated on days (d) −6 and −4 (475–975 mg/m 2 /day), followed by Clo (40 mg/m 2 /day) and Bu (target AUC, 4000 μMol min/day) (d −6 to −3). CD20 + tumors received rituximab. GVHD prophylaxis included ATG (MUD), tacrolimus and MMF. We compared their outcomes to matched-pair concurrent controls receiving Flu/Mel + matched allo-SCT. We enrolled 64 patients, median age 46 (17–63), 31 B-NHL/22 T-NHL/11 Hodgkin, 36 MSD/28 MUD (all PBPC), median 4 (2–10) prior therapies; 18 prior auto-SCT, 42 active diseases at allo-SCT (12 PD). Toxicities (mucositis and transaminitis) were manageable. Gem/Clo/Bu was myeloablative yielding early full donor chimerism. Grades II–IV/III–IV acute GVHD rates of 37% and 18%; chronic GVHD of 33% (13% severe); NRM at D100/1 year was 7% and 18%. ORR/CR rates: 78%/71% (B-NHL), 93%/93% (T-NHL), 67%/67% (Hodgkin). At a median follow-up of 60 (12–110) months, EFS/OS rates: 36%/47%. Gem/Clo/Bu patients had better median EFS (12 vs. 3 months, P = 0.001) and OS (25 vs. 7 months, P = 0.003) than 113 Flu/Mel matched-pair controls. The new myeloablative regimen Gem/Clo/Bu has limited toxicity and high activity in allo-SCT for aggressive lymphomas, yielding better outcomes than concurrent matched-pair controls receiving Flu/Mel.

oncology,immunology,hematology,transplantation
Peripheral Blood Mononuclear Cells (PB-MNCs) for the treatment of chronic tissue dystrophy in a complex case of lower limb reconstruction

S Carella,L Patanè,M Castrechini,F Lo Torto,G Marruzzo,U Redi,M Greco,D Ribuffo,M G Onesti

DOI: https://doi.org/10.26355/eurrev_202405_36295

Abstract:Background: Recently, the infiltration of a subpopulation of cells represented by mononucleated cells extracted from peripheral blood [Peripheral Blood-Mononuclear Cells (PB-MNCs)] is becoming a useful technique for medical and surgical regenerative procedures. Due to the angiogenetic and regenerative properties of PB-MNCs, the infiltration of these cells is, in our opinion, a new option indicated in the treatment of pathologies characterized by tissue dystrophy, loss of vascularization, and non-healing wounds. Case presentation: A 25-year-old active smoker patient was diagnosed with Rhabdomyosarcoma of the anterior tibial muscle of his left leg and treated with neoadjuvant chemo- and radiotherapy (RT). After the tumor excision, the patient developed wound dehiscence with bone exposure and a perilesional radiation-induced chronic dermatitis characterized by skin dyschromia and hair thinning along the treated area. The patient underwent surgical debridement and reconstruction with autologous skin grafts and dermal substitutes, with poor outcomes due to graft failure. The patient was subsequently treated with surgical debridement and coverage with a reverse sural fascia-cutaneous flap. After 13 days, wound dehiscence was observed, and reconstruction of the dehiscent areas was performed with a split-thickness autologous skin graft with no success. After wound debridement, a new split-thickness skin graft was performed, and a concentrate of autologous PB-MNCs was injected in the flap and perilesional skin. After 14 days, graft take was reached, and improvements in perilesional tissue tropism were noted. At 2 months follow-up, the patient appeared completely healed. Conclusions: In our opinion, the use of PB-MNCs to treat conditions characterized by tissue dystrophy, which require neoangiogenesis and cell regeneration, can be a useful and unconsidered technique that could be utilized to improve tissue tropism. Furthermore, prospective trials are necessary to validate our observations.
Allogeneic transplantation after immunotherapy for relapsed/refractory non-Hodgkin lymphoma: a comparison with a historical cohort

Jacopo Mariotti,Cristina Zucchinetti,Laura Giordano,Chiara De Philippis,Daniele Mannina,Barbara Sarina,Daniela Taurino,Rachele Carbon,Armando Santoro,Stefania Bramanti

DOI: https://doi.org/10.1016/j.jcyt.2024.05.002

IF: 6.196

Cytotherapy

Abstract:Background aims: New immunotherapy drugs, such as bispecific T-cell engager antibodies, checkpoint inhibitors and antibody-drug conjugates, are commonly used as salvage therapy for patients with non-Hodgkin lymphoma relapsing after chimeric antigen receptor (CAR) T-cell therapy. Nevertheless, their potential long-term effects on the outcome of allogeneic stem cell transplantation (Allo-SCT) are not well known. Methods: We retrospectively analyzed the outcomes of 27 relapsed/refractory non-Hodgkin lymphoma patients receiving Allo-SCT after immunotherapy in the pre-CAR T-cell therapy era and compared them with a historical cohort of 28 subjects undergoing Allo-SCT after conventional therapy. Results: The two cohorts had similar outcomes in terms of graft-versus-host disease/relapse-free survival (4 years, 59% versus 46%), overall survival (4 years, 77% versus 44%), non-relapse mortality (4 years, 19% versus 22%) and acute (6 months, 15% versus 21%) and chronic (4 years, 18% versus 24%) graft-versus-host disease. Of note, the cumulative incidence of relapse was lower after immunotherapy (4 years, 4% versus 14%), although significance was not reached. The cumulative incidence of cytomegalovirus and fungal infection did not differ among the two cohorts. Conclusions: Consolidation with Allo-SCT is a safe and curative option for patients achieving disease response after new immunotherapy drugs that could represent a desirable salvage strategy for patients relapsing after CAR T-cell therapy.
Combining CD34+ stem cell selection with prophylactic pathogen and leukemia directed T‐cell immunotherapy to simultaneously reduce graft versus host disease, infection and leukemia recurrence after allogeneic stem cell transplant

David J. Gottlieb,Gaurav Sutrave,Wei Jiang,Selmir Avdic,Janine A. Street,Renee Simms,Leighton E. Clancy,Vicki Antonenas,Brian S. Gloss,Caroline Bateman,David C. Bishop,Kenneth P. Micklethwaite,Emily Blyth

DOI: https://doi.org/10.1002/ajh.26594

IF: 13.265

2022-05-14

American Journal of Hematology

Abstract:Background We designed a trial to simultaneously address the problems of graft versus host disease (GVHD), infection and recurrence of malignancy after allogeneic stem cell transplantation. Methods CD34+ stem cell isolation was used to minimise the development of acute and chronic GVHD. Two prophylactic infusions, one combining donor‐derived cytomegalovirus, Epstein Barr virus and Aspergillus fumigatus specific T‐cells and the other comprising donor‐derived CD19 directed chimeric antigen receptor (CAR) bearing T‐cells, were given 21‐28 days after transplant. Two patients were transplanted for acute lymphoblastic leukemia from HLA identical siblings using standard doses of cyclophosphamide and total body irradiation without antilymphocyte globulin. Patients received no post‐transplant immune suppression and were given no pre‐CAR T‐cell lymphodepletion. Results Neutrophil and platelet engraftment was prompt. Following adoptive T‐cell infusions there was rapid appearance of antigen experienced CD8+ and to a lesser extent CD4+ T‐cells. Tetramer positive T‐cells targeting CMV and EBV appeared rapidly after T‐cell infusion and persisted for at least one year. CAR T‐cell expansion occurred and persisted for up to 3 months. T‐cell receptor tracking confirmed the presence of product derived T‐cell clones in blood targeting all three pathogens. Both patients are alive over 3 years post‐transplant without evidence of GVHD or disease recurrence. Conclusion Combining robust donor T‐cell depletion with directed T‐cell adoptive immunotherapy targeting infectious and malignant antigens permits independent modulation of GVHD, infection and disease recurrence. The combination may separate GVHD from the graft versus tumor effect, accelerate immune reconstitution and improve transplant tolerability. This article is protected by copyright. All rights reserved.

hematology
Oligometastatic breast cancer and metastasis-directed treatment: an aggressive multimodal approach to reach the cure

Filippo Merloni,Michela Palleschi,Chiara Casadei,Antonino Romeo,Annalisa Curcio,Roberto Casadei,Franco Stella,Giorgio Ercolani,Caterina Gianni,Marianna Sirico,Simona Cima,Samanta Sarti,Lorenzo Cecconetto,Giandomenico Di Menna,Ugo De Giorgi

DOI: https://doi.org/10.1177/17588359231161412

2023-01-01

Therapeutic Advances in Medical Oncology

Abstract:Metastatic breast cancer (BC) is considered an incurable disease and is usually treated with palliative intent. However, about 50% of metastatic BCs present with only a few metastatic lesions and are characterized by longer overall survival. These patients, defined as oligometastatic, could benefit from a multimodal approach, which combines systemic therapy with metastasis-directed treatment (stereotactic ablative therapy or surgery). The current definition of oligometastatic seems incomplete since it is based only on imaging findings and does not include biological features, and the majority of relevant data supporting this strategy comes from retrospective or non-randomized studies. However, the chance of reaching long-term complete remission or even a cure has led to the development of randomized trials investigating the impact of combined treatment in oligometastatic BC (OMBC). The SABR-COMET trial, the first randomized study to include BC patients, showed promising results from a combination of stereotactic ablative radiotherapy and systemic therapy. Considering the randomized trial’s results, multidisciplinary teams should be set up to select OMBC patients who could achieve long-term survival with aggressive multimodal treatment.

oncology
Adaptive Bayesian Detection Using MIMO Radar in Spatially Heterogeneous Clutter

Tianxian Zhang,G. Cui,L. Kong,Xiaobo Yang

DOI: https://doi.org/10.1109/LSP.2013.2255272

2013-03-27

IEEE Signal Processing Letters

Abstract:This letter considers adaptive target detection problem using multiple-input multiple-output (MIMO) radar in the presence of spatially heterogeneous clutter. The covariances of the primary data and secondary data for the same and different transmit-receive pairs are modeled as different random matrices with partial priori knowledge of the environment. Two-step strategy is employed to design adaptive detector. Specifically, we first obtain the generalized likelihood ratio test (GLRT) detector by assuming the known matrices. Then, we derive the maximum posteriori (MAP) estimator of the covariance matrices by exploiting the priori information, and replace the given covariance matrices in the obtained GLRT with MAP estimates. Finally, we evaluate the proposed adaptive detector via numerical simulations.
[Treatment of Malignant Lymphoma by Autologous Hematopoietic Stem Cell Transplantation Combined with High Dose Radiotherapy and Chemotherapy].

H. Wang,X. Cui,X. Liu,H. Zhang,X. Hao

DOI: https://doi.org/10.3760/j:issn:0376-2491.2003.11.013

IF: 51.769

2008-01-01

Annals of Oncology

Abstract:OBJECTIVE:To investigate the effects of treatment of malignant lymphoma (ML) by autologous hematopoietic stem cell transplantation (AHSCT) combined with high dose radiotherapy and chemotherapy.METHODS:From June 1991 to October 2002, 56 patients, aged 9 - 65 years, with ML, 44 non-Hodgkin's lymphoma (NHL) and 12 Hodgkin's disease (HD) were treated with AGSCT combined with high dose radiotherapy and chemotherapy. Among them, 12 received autologous bone marrow transplantation (ABMT) and 44 received autologous peripheral blood stem cell transplantation (APBSCT), In the latter the APBSCs were mobilized by carboplatin and etoposide (CE) or CHOP (CTX, ADM, VCR, PDN) plus granulocyte-colony stimulating factor (G-CSF) and/or granulocyte-macrophage colony stimulating factor (GM-CSF) 10 micro g/kg/d. Pretreatment included BEAM (BCNU, Vp-16, AraC, MEL) or MEL 140 mg/m(2) + Vp-16,200 mg/L total body irradiation (TBI) 8 Gy. The patients were flowed up for 40 - 4,310 days with a median of 1,820 days.RESULTS:Hematopoietic reconstruction was observed in all patients. The 1, 2, and 5-year disease-free survival rates were 87.5%, 60.7%, and 57.1% respectively, with the longest survival of 11 years. Fourteen patients developed relapse. No transplantation-related death was seen.CONCLUSION:Autologous hematopoietic stem cell transplantation combined with high dose radiotherapy and chemotherapy is effective on Ml. AHSCT shows a more rapid effect on hematopoietic reconstruction than ABMT.
The use of bispecific antibodies to optimize the outcome of patients with acute leukemia, lymphoma and multiple myeloma after SCT

Hermann Einsele,Leo Rasche,Max S. Topp,K. Martin Kortüm,Johannes Duell

DOI: https://doi.org/10.1038/s41409-019-0596-z

2019-08-01

Bone Marrow Transplantation

Abstract:One of the remaining and unresolved problems in allogeneic stem cell transplantation, especially following a T cell-depleted transplant as often performed in the setting of haploidentical transplantation, is the relapse of the underlying hematological malignancy. It has been demonstrated that in the last years we have made major progress in controlling infections, acute and chronic GvHD and making stem cell transplantation available to elderly patients. However, little improvement has been made to achieve better tumor control and to lower the relapse rate. Thus, novel immunotherapeutic strategies are increasingly used prior to or even following allogeneic stem cell transplantation to better control the underlying malignancy and thus, to reduce the relapse rate. These novel immunotherapeutic strategies comprise monoclonal antibodies, immunotoxins and even more effective T cell redirecting strategies like bispecific antibodies and T cells transduced with either chimeric antigen receptors (CAR) or (affinity-tuned) T cell receptors (TCR).

oncology,immunology,hematology,transplantation
Autotransplantation for advanced lymphoma and Hodgkin's disease followed by post-transplant rituxan/GM-CSF or radiotherapy and consolidation chemotherapy

A P Rapoport,B Meisenberg,C Sarkodee-Adoo,A Fassas,S R Frankel,B Mookerjee,N Takebe,R Fenton,M Heyman,A Badros,A Kennedy,M Jacobs,R Hudes,K Ruehle,R Smith,L Kight,S Chambers,M MacFadden,M Cottler-Fox,T Chen,G Phillips,G Tricot

DOI: https://doi.org/10.1038/sj.bmt.1703363

Abstract:Disease relapse occurs in 50% or more of patients who are autografted for relapsed or refractory lymphoma (NHL) or Hodgkin's disease (HD). The administration of non-cross-resistant therapies during the post-transplant phase could possibly control residual disease and delay or prevent its progression. To test this approach, 55 patients with relapsed/refractory or high-risk NHL or relapsed/refractory HD were enrolled in the following protocol: stem cell mobilization: cyclophosphamide (4.5 g/m(2)) + etoposide (2.0 g/m(2)) followed by GM-CSF or G-CSF; high-dose therapy: gemcitabine (1.0 g/m(2)) on day -5, BCNU (300 mg/m(2)) + gemcitabine (1.0 g/m(2)) on day -2, melphalan (140 mg/m(2)) on day -1, blood stem cell infusion on day 0; post-transplant immunotherapy (B cell NHL): rituxan (375 mg/m(2)) weekly for 4 weeks + GM-CSF (250 microg thrice weekly) (weeks 4-8); post-transplant involved-field radiotherapy (HD): 30-40 Gy to pre-transplant areas of disease (weeks 4-8); post-transplant consolidation chemotherapy (all patients): dexamethasone (40 mg daily)/cyclophosphamide (300 mg/m(2)/day)/etoposide (30 mg/m(2)/day)/cisplatin (15 mg/m(2)/day) by continuous intravenous infusion for 4 days + gemcitabine (1.0 g/m(2), day 3) (months 3 + 9) alternating with dexamethasone/paclitaxel (135 mg/m(2))/cisplatin (75 mg/m(2)) (months 6 + 12). Of the 33 patients with B cell lymphoma, 14 had primary refractory disease (42%), 12 had relapsed disease (36%) and seven had high-risk disease in first CR (21%). For the entire group, the 2-year Kaplan-Meier event-free survival (EFS) and overall survival (OS) were 30% and 35%, respectively, while six of 33 patients (18%) died before day 100 from transplant-related complications. The rituxan/GM-CSF phase was well-tolerated by the 26 patients who were treated and led to radiographic responses in seven patients; an eighth patient with a blastic variant of mantle-cell lymphoma had clearance of marrow involvement after rituxan/GM-CSF. Of the 22 patients with relapsed/refractory HD (21 patients) or high-risk T cell lymphoblastic lymphoma (one patient), the 2-year Kaplan-Meier EFS and OS were 70% and 85%, respectively, while two of 22 patients (9%) died before day 100 from transplant-related complications. Eight patients received involved field radiation and seven had radiographic responses within the treatment fields. A total of 72 courses of post-transplant consolidation chemotherapy were administered to 26 of the 55 total patients. Transient grade 3-4 myelosuppression was common and one patient died from neutropenic sepsis, but no patients required an infusion of backup stem cells. After adjustment for known prognostic factors, the EFS for the cohort of HD patients was significantly better than the EFS for an historical cohort of HD patients autografted after BEAC (BCNU/etoposide/cytarabine/cyclophosphamide) without consolidation chemotherapy (P = 0.015). In conclusion, post-transplant consolidation therapy is feasible and well-tolerated for patients autografted for aggressive NHL and HD and may be associated with improved progression-free survival particularly for patients with HD.
HLA-mismatched hematopoietic SCT without in vitro T-cell depletion for myelodysplastic syndrome

Y Chen,K Liu,L Xu,H Chen,D Liu,X Zhang,H Shi,W Han,Y Wang,T Zhao,J Wang,J Wang,X Huang

DOI: https://doi.org/10.1038/bmt.2009.351

2010-01-01

Bone Marrow Transplantation

Abstract:Allogeneic hematopoietic SCT (HSCT) is currently the only curative treatment for myelodysplastic syndrome (MDS). However, many patients cannot find an HLA-matched donor. We have developed a new protocol for HLA-mismatched (including haploidentical) HSCT using G-CSF-primed BM plus G-CSF-mobilized PBSCs without in vitro T-cell depletion. A total of 36 patients diagnosed with high-risk MDS (RAEB (refractory anemia with excess blasts) or RAEBt (RAEB in transformation)) underwent transplantation from HLA-mismatched family donors. All patients achieved sustained myeloid engraftment. The cumulative incidence of grades II–IV acute GVHD (aGVHD) was 60% and that of grades III and IV aGVHD was 15%. The 2-year cumulative incidence of chronic GVHD was 56%. After a median follow-up of 17 months, 4 patients had relapsed and died and 25 patients were still alive. The 2-year probability of leukemia-free survival (LFS) was 65%. Patients transplanted within 7 months of diagnosis had better LFS (89 vs 43% ). Severe aGVHD decreased the LFS significantly by increasing non-relapse mortality (NRM). This study confirms that HLA-mismatched HSCT is a treatment option for MDS. Patients with high-risk MDS benefit from receiving HSCT early in the course of the disease.
Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma; Insights into Its Potential Role in the Era of New Immunotherapeutic and Targeted Therapies: The GETH/GELTAMO Experience

Antonio Gutierrez,Leyre Bento,Silvana Novelli,Alejandro Martin,Gonzalo Gutierrez,Maria Queralt Salas,Mariana Bastos-Oreiro,Ariadna Perez,Rafael Hernani,Maria Cruz Viguria,Oriana Lopez-Godino,Juan Montoro,Jose Piñana,Christelle Ferra,Rocio Parody,Carmen Martin,Ignacio Español,Lucrecia Yañez,Guillermo Rodriguez,Joud Zanabili,Pilar Herrera,Maria Varela,Antonia Sampol,Carlos Solano,Dolores Caballero,on behalf of the Grupo Español de Trasplante de Progenitores Hematopoyéticos (GETH) and Grupo Español de Linfoma y Trasplante Autólogo (GELTAMO)

DOI: https://doi.org/10.3390/cancers14112673

2022-05-28

Cancers

Abstract:Allo-SCT is a curative option for selected patients with relapsed/refractory (R/R) MCL, but with significant NRM. We present the long-term results of patients receiving allo-SCT in Spain from March 1995 to February 2020. The primary endpoints were EFS, OS, and cumulative incidence (CI) of NRM, relapse, and GVHD. We included 135 patients, most (85%) receiving RIC. After a median follow-up of 68 months, 5-year EFS and OS were 47 and 50%, respectively. Overall and CR rates were 86 and 80%. The CI of relapse at 1 and 3 years were 7 and 12%. NRM at day 100 and 1 year were 17 and 32%. Previous ASCT and Grade 3–4 aGVHD were associated with a higher NRM. Grade 3–4 aGVHD, donor type (mismatch non-related), and the time-period 2006–2020 were independently related to worse EFS. Patients from 1995–2005 were younger, most from HLA-identical sibling donors, and were pretreated less. Our data confirmed that allo-SCT may be a curative option in R/R MCL with low a CI of relapse, although NRM is still high, being mainly secondary to aGVHD. The arrival of new, highly effective and low toxic immunotherapeutic or targeted therapies inevitably will relegate allo-SCT to those fit patients who fail these therapies, far away from the optimal timing of treatment.

oncology
Allogeneic haematopoietic cell transplantation for therapy-related myeloid neoplasms arising following treatment for lymphoma: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT

Mitja Nabergoj,Diderik-Jan Eikema,Linda Koster,Uwe Platzbecker,Katja Sockel,Jürgen Finke,Nicolaus Kröger,Edouard Forcade,Arnon Nagler,Matthias Eder,Johanna Tischer,Annoek E. C. Broers,Jürgen Kuball,Keith M. O. Wilson,Mathilde Hunault-Berger,Matthew Collin,Domenico Russo,Lucía López Corral,Grzegorz Helbig,Alberto Mussetti,Christof Scheid,Carmelo Gurnari,Kavita Raj,Joanna Drozd-Sokolowska,Ibrahim Yakoub-Agha,Marie Robin,Donal P. McLornan

DOI: https://doi.org/10.1038/s41409-023-02193-z

2024-01-12

Bone Marrow Transplantation

Abstract:Therapy-related myeloid neoplasms (t-MN), either myelodysplastic neoplasms (t-MDS) or acute myeloid leukemias (t-AML), have a poor prognosis and allogeneic haematopoietic cell transplantation (allo-HCT) represents the only curative option. In this multicenter, registry-based study, we analyzed outcomes of 378 patients undergoing first allo-HCT between 2006–2017 for t-MN arising secondary to lymphoma treatment. Median age was 58 years at allo-HCT; 222 (59%) had a diagnosis of t-MDS and 156 (41%) of t-AML, respectively. At the time of allo-HCT, 46% of t-MN cases were reported as in complete remission (CR) and 15% of lymphomas were recorded as not in remission. A reduced intensity conditioning regimen was used in 70% of cases. For the entire cohort, 5-year OS, and t-MN PFS, relapse incidence and NRM were 32%, 28%, 35% and 37%, respectively. In multivariable analysis, undergoing allo-HCT with t-MN not in CR and older age were associated with significantly worse OS, PFS and NRM. At 5 years post allo-HCT, the relapse incidence of lymphoma was low at 3%, while the rate of secondary malignancies was 8%. This analysis shows the curative potential of allo-HCT for patients with t-MN arising secondary to lymphoma treatment in approximately a third of patients.

oncology,immunology,hematology,transplantation
Successful Bridging to Allogeneic Transplantation With Valemetostat in Two Refractory/relapsed Peripheral T-cell lymphoma patients

Gianmarco Bagnato,Vittorio Stefoni,Alessandro Broccoli,Lisa Argnani,Cinzia Pellegrini,Beatrice Casadei,Francesca Bonifazi,Pier Luigi Zinzani

DOI: https://doi.org/10.4084/mjhid.2024.004

2024-01-01

Mediterranean Journal of Hematology and Infectious Diseases

Abstract:We report the case of 2 patients with relapsed/refractory peripheral T-cell lymphoma treated with valemetostat tosilate, a selective dual inhibitor of histone-lysine N-methyltransferases enhancer of zeste homolog 1 and 2, and subsequently bridged to allogeneic stem cell transplantation. Valemetostat led to a quick response and was well tolerated, offering as a promising bridge therapy to transplantation for patients with relapsed/refractory peripheral T-cell lymphoma which is still an unmet medical need.

infectious diseases,hematology
Remission of relapsed/refractory classical Hodgkin lymphoma induced by brentuximab vedotin and pembrolizumab combination after allogeneic hematopoietic stem cell transplantation: a case report

Federica Giannotti,Carmen De Ramon Ortiz,Federico Simonetta,Sarah Morin,Chiara Bernardi,Stavroula Masouridi-Levrat,Yves Chalandon,Anne-Claire Mamez

DOI: https://doi.org/10.3389/fimmu.2024.1360275

IF: 7.3

2024-03-06

Frontiers in Immunology

Abstract:Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potentially curative treatment option for patients with highly chemorefractory Hodgkin lymphoma (HL). The CD30-targeting antibody-drug conjugate Brentuximab-Vedotin (BV) and programmed cell death protein-1 (PD-1) blocking agents have demonstrated clinical activity with durable responses in relapsed/refractory (r/r) HL. However, patients with a history of allo-HSCT were frequently excluded from clinical trials due to concerns about the risk of graft-versus-host disease (GVHD). We report the clinical history of a patient with refractory classical HL who underwent two allo-HSCTs (first from matched unrelated and second from haploidentical donor) after relapsing on BV and nivolumab and for whom durable remission was finally obtained using BV-pembrolizumab combination for relapse after haploidentical HSCT. Such treatment was associated with the onset of GVHD after only two cycles which led to treatment discontinuation. However, the side effects were rapidly controlled, and after 2 years of follow-up, the patient is still in remission. Our data support the feasibility and efficacy of combining PD-1 blockade with BV to enhance the graft-versus-lymphoma effect after allo-HSCT.

immunology
Submyeloablative total body irradiation‐based conditioning and allogeneic stem cell transplantation in high‐risk myeloma with early progression after up‐front autologous transplantation

Elias K. Mai,Thomas Schmitt,Aleksandar Radujkovic,Laila König,Hartmut Goldschmidt,Anthony D. Ho,Thomas Luft,Carsten Müller‐Tidow,Peter Dreger,Ute Hegenbart,Stefan O. Schönland

DOI: https://doi.org/10.1111/bjh.17779

2021-08-24

British Journal of Haematology

Abstract:Table I. Treatment, feasibility, and effectiveness of allogeneic stem cell transplantation. VariableValueAllogeneic transplantationTime from initial MM therapy to alloSCT, days, median (range)714 (350–2833)Age at alloSCT, years, median (range)50 (34–64)Previous lines of therapy prior to alloSCT reinductionMedian (range)1 (1–8)1 prior line of therapy prior to alloSCT reinduction, n/N (%) 21/32 (65·6)>1 prior line of therapy prior to alloSCT reinduction, n/N (%) 11/32 (34·4)Reinduction prior to alloSCT, n/N (%) PI-based10/32 (31·3)IMiD-based10/32 (31·3)PI + IMiD-based6/32 (18·8)PI + moAb-based1/32 (3·1)IMiD + moAb-based1/32 (3·1)Other4/32 (12·4)Number of agents used for reinduction prior to alloSCT, n/N (%) Doublet7/32 (21·8)Triplet16/32 (50·0)Quadruplet (or more)6/32 (18·8)Other3/32 (9·4)Duration of re-induction prior to alloSCT, days, median (range)140 (54–336)Response prior to alloSCT, n/N (%) SD/MR or better32/32 (100)PR or better29/32 (90·6)VGPR or better12/32 (37·5)Donor status, n/N (%) MSD (10/10, family)10/32 (31·3)MUD (10/10, unrelated)19/32 (59·3)MMUD (9/10, unrelated)3/32 (9·4)Stem cell source, n/N (%) PB31/32 (96·9)BM1/32 (3·1)Conditioning regimen, n/N (%) TBI 8 Gy/CYC29/32 (90·7)TBI 8 Gy/FLU1/32 (3·1)TBI 6 Gy/CYC1/32 (3·1)TBI 6 Gy/FLU1/32 (3·1)ATG prior to alloSCT, n/N (%) -Abstract Truncated-

hematology
[Salvage Trerapy for Patients with Relapsed and Refractory Lymphoma by Allogeneic Hematopoietic Stem Cell Transplantation].

Yue Yin,Zhi-Xiang Qiu,Yuan Li,Wei-Lin Xu,Yu-Hua Sun,Wei Liu,Wen-Sheng Wang,Mang-Ju Wang,Li-Hong Wang,Yu-Jun Dong,Jin-Ping Ou,Xi-Nan Cen,Han-Yun Ren

DOI: https://doi.org/10.7534/j.issn.1009-2137.2017.02.020

2017-01-01

Abstract:OBJECTIVE:To assess the safety and efficacy of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in treating patients with relapsed and refractory lymphoma.METHODS:Thirty-one consecutive patients with relapsed or refractory lymphoma received allo-HSCT. Used conditioning regimens included conditioning based on BEAM regimen(12 cases), conditioning based on modified Bu/Cy regimen(11 cases), conditioning based on Cy/TBI regemen(6 cases) and conditioning of Bu/Cy regimen(1 case). For provention of GVHD, the MMF was used on the basis of classcal protocol consisting of CsA combined with MTX. The infused HSC included the HLA-matched related HSC(11 cases), HLA nonidentical related HSC(13 cases) and HLA-matched unrelated HSC(6 cases). The bone marrow plus peripheral blood HSC were infused in 21 cases, while only peripheral blood HSC were infused in 9 cases. Among the 31 cases of relapse/refractory lymphoma, 18 patients were male and 13 were female, 4 cases were Hodgkin's lymphoma and 27 cases were non-Hodgkin's lymphoma. ALL of the 31 patients were qualified, as they were not in complete remission (CR) or in advanced stage at the time of transplantation.RESULTS:Twenty-seven evaluable patients showed the engraftment of both neutrophil and platelet at a median of 12 days(range 10-20) and 13 days(range 9-34) respectively, 9 cases developed II-IV aGVHD, and cGVHD was observed in 3 patients, 5 patients can not achieve CR at 3 months after transplantation, and 6 patients relapsed after CR, the median follow-up of all the 31 patients after transplantation was 11.5 months (ranged, 0-141 months), and the 2-year OS was 46.1%±9.5% with median survival of 40 (9-141) months in the 15 survivors. The age (P<0.05), disease status before transplantation (P=0.020) and remission after transplantation(P=0.000) were significantly related with survival. Cox's proportional hazards regression model analysis showed that the age (P=0.041) and disease statue (P=0.020) before allo-HSCT were independent predictive factors for survival.CONCLUSION:Allo-HSCT is an optimal treatment strategy for the patients with relapsed and refractory lymphoma who failed to most, if not all, available options.
Allogeneic hematopoietic stem cell transplantation for advanced mycosis fungoides and Sézary syndrome. An updated experience of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation

E. Domingo-Domenech,R. F. Duarte,A. Boumedil,F. Onida,I. Gabriel,H. Finel,W. Arcese,P. Browne,D. Beelen,G. Kobbe,H. Veelken,R. Arranz,H. Greinix,S. Lenhoff,X. Poiré,J. M. Ribera,J. Thompson,T. Zuckerman,G. J. Mufti,A. Cortelezzi,E. Olavarria,P. Dreger,A. Sureda,S. Montoto

DOI: https://doi.org/10.1038/s41409-020-01197-3

2021-01-08

Bone Marrow Transplantation

Abstract:Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potentially curative treatment option in advanced-stage mycosis fungoides (MF) and Sézary syndrome (SS). This study presents an updated analysis of the initial experience of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (EBMT) describing the outcomes after allo-HSCT for MF and SS, with special emphasis on the impact of the use of unrelated donors (URD).

oncology,immunology,hematology,transplantation

Combined use of autografting and non-myeloablative allografting for the treatment of hematologic malignancies and metastatic breast cancer.

[Clinical Observation of Gleevec Combined with Myeloablative Allogeneic Stem Cells Transplantation in Treatment of Chronic Myeloid Leukemia].

Hla-Haploidentical Stem Cell Transplantation for Malignant Hematological Diseases Using G-Csf Mobilized Bone Marrow and Peripheral Blood Stem Cells

Steady-state low thermal resistance characterization apparatus: The bulk thermal tester.

High activity of the new myeloablative regimen of gemcitabine/clofarabine/busulfan for allogeneic transplant for aggressive lymphomas

Peripheral Blood Mononuclear Cells (PB-MNCs) for the treatment of chronic tissue dystrophy in a complex case of lower limb reconstruction

Allogeneic transplantation after immunotherapy for relapsed/refractory non-Hodgkin lymphoma: a comparison with a historical cohort

Combining CD34+ stem cell selection with prophylactic pathogen and leukemia directed T‐cell immunotherapy to simultaneously reduce graft versus host disease, infection and leukemia recurrence after allogeneic stem cell transplant

Oligometastatic breast cancer and metastasis-directed treatment: an aggressive multimodal approach to reach the cure

Adaptive Bayesian Detection Using MIMO Radar in Spatially Heterogeneous Clutter

[Treatment of Malignant Lymphoma by Autologous Hematopoietic Stem Cell Transplantation Combined with High Dose Radiotherapy and Chemotherapy].

The use of bispecific antibodies to optimize the outcome of patients with acute leukemia, lymphoma and multiple myeloma after SCT

Autotransplantation for advanced lymphoma and Hodgkin's disease followed by post-transplant rituxan/GM-CSF or radiotherapy and consolidation chemotherapy

HLA-mismatched hematopoietic SCT without in vitro T-cell depletion for myelodysplastic syndrome

Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma; Insights into Its Potential Role in the Era of New Immunotherapeutic and Targeted Therapies: The GETH/GELTAMO Experience

Allogeneic haematopoietic cell transplantation for therapy-related myeloid neoplasms arising following treatment for lymphoma: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT

Successful Bridging to Allogeneic Transplantation With Valemetostat in Two Refractory/relapsed Peripheral T-cell lymphoma patients

Remission of relapsed/refractory classical Hodgkin lymphoma induced by brentuximab vedotin and pembrolizumab combination after allogeneic hematopoietic stem cell transplantation: a case report

Submyeloablative total body irradiation‐based conditioning and allogeneic stem cell transplantation in high‐risk myeloma with early progression after up‐front autologous transplantation

[Salvage Trerapy for Patients with Relapsed and Refractory Lymphoma by Allogeneic Hematopoietic Stem Cell Transplantation].

Allogeneic hematopoietic stem cell transplantation for advanced mycosis fungoides and Sézary syndrome. An updated experience of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation